Welcome to our dedicated page for CELLBXHEALTH PLC news (Ticker: ANPCY), a resource for investors and traders seeking the latest updates and insights on CELLBXHEALTH PLC stock.
CelLBxHealth plc, formerly known as ANGLE plc and represented in the United States as ANGLE PLC S/ADR (symbol ANPCY), regularly issues news updates that describe its progress in circulating tumour cell (CTC) intelligence and liquid biopsy. Company announcements highlight developments around its Parsortix® platform, collaborations with pharmaceutical and medtech partners, and strategic decisions affecting its business direction and branding.
News items often cover clinical and scientific milestones, such as proof-of-concept studies in indications like glioblastoma and integrations of the Parsortix workflow with established diagnostic platforms, including Roche Tissue Diagnostics’ BenchMark ULTRA system. Releases also describe participation in major oncology and drug development conferences, where the company presents data on CTC detection, biomarker analysis and potential applications in areas such as antibody-drug conjugate development.
Investors and researchers following ANPCY-related news will also see updates on commercial contracts and collaborations. The company has reported completing contracts with large pharmaceutical companies, ongoing services agreements with biopharma partners, and a collaboration with Myriad Genetics to adapt an existing tissue-based cancer test to a CTC-based format using Parsortix. Interim results and strategy updates provide context on revenue mix between pharma services and product sales, as well as commentary on external market conditions.
Corporate governance and board or management changes are another recurring theme. Recent announcements include the transition from ANGLE plc to CelLBxHealth plc, the appointment of an Executive Chairman, subsequent changes to the board, and later the appointment of a Chief Executive Officer and additional non-executive directors. These updates are presented alongside information on funding plans and cash runway.
For readers tracking ANPCY, the news stream offers a consolidated view of how CelLBxHealth is advancing CTC-based technologies, engaging with global partners, and refining its strategy in response to scientific opportunities and market conditions.
ANGLE plc (OTCQX:ANPCY) will present at the Jefferies London Healthcare Conference on November 16 at 10:00 AM GMT. The conference is the largest healthcare-focused investor event in Europe and features CEO Andrew Newland and CFO Ian Griffiths. ANGLE's innovative Parsortix liquid biopsy technology enables comprehensive cancer analysis through non-invasive blood tests, with a CE Mark in Europe and a pending FDA submission for breast cancer applications. The company is advancing clinical studies to enhance ovarian cancer detection accuracy.
ANGLE plc (OTCQX:ANPCY) presented findings at the NCRI Festival indicating that longitudinal analysis of circulating tumor cells (CTCs) using the Parsortix system can effectively predict treatment response in metastatic prostate cancer patients undergoing docetaxel therapy. The study revealed that the KLK2 gene expression on CTCs was a more reliable biomarker for assessing cancer progression than current PSA levels. This non-invasive method could allow for early detection of treatment resistance, improving patient outcomes by enabling timely treatment adjustments, as prostate cancer rates continue to rise significantly.
ANGLE plc announced the issuance of 31,666 new ordinary shares following the exercise of employee options. The new shares, priced at £0.10 each, rank pari passu with existing shares, bringing the total to 234,973,717. An application for their admission to trading on AIM has been submitted, with trading set to begin at 8:00 a.m. on November 16, 2021. This move is part of ANGLE's ongoing efforts to enhance its liquid biopsy technology and maintain its competitive position in the healthcare market.
ANGLE plc (OTCQX:ANPCY) announced a change in its advisory team, appointing Berenberg as its Nominated Adviser and Joint Broker, and Jefferies as its Joint Broker, effective immediately. This strategic move aims to strengthen the company's market position as a leading liquid biopsy enterprise. ANGLE's proprietary Parsortix system, which targets circulating tumor cells for cancer analysis, is progressing towards FDA clearance for use with metastatic breast cancer patients and has shown promising results in clinical studies for ovarian cancer diagnostics.
ANGLE plc has announced the issuance of 15,666 new ordinary shares following employee option exercises. The New Ordinary Shares will rank equally with existing shares and are expected to be admitted for trading on AIM on October 27, 2021. This brings the total number of ordinary shares to 234,942,051, enhancing total voting rights.
ANGLE specializes in liquid biopsy technologies, particularly the Parsortix system, which captures circulating tumor cells for cancer analysis. The company continues to progress its clinical studies and patent portfolio.
ANGLE plc (OTCQX: ANPCY) announced the issuance of 30,000 new ordinary shares following the exercise of employee options. These shares will rank equally with existing shares and are expected to be admitted for trading on AIM on October 21, 2021. After this issuance, the total number of ordinary shares in circulation will be 234,926,385, impacting the total voting rights accordingly. ANGLE is recognized for its liquid biopsy technology, particularly the Parsortix system, which captures cancer cells for further analysis.
ANGLE plc (OTCQX: ANPCY), a leader in liquid biopsy technology, announced the issuance of 48,334 new ordinary shares following employee option exercises. These shares will rank equally with existing shares, bringing the total to 234,896,385 shares post-admission. The shares are expected to be traded on AIM starting October 6, 2021. This move does not directly reflect on revenue or market performance but indicates continued employee engagement and corporate governance.
ANGLE plc (OTCQX: ANPCY) reported its interim results for the six months ended June 30, 2021. Revenue rose to £0.3 million from £0.2 million in H1 2020, while losses increased to £7.7 million from £3.4 million. The company is progressing with its FDA submission for the Parsortix system, expecting a response in H2 2021. A new global pharma services business has been launched, with contracts in progress. The ovarian cancer clinical study is nearing completion, with results anticipated in Q4 2021.
ANGLE plc has announced significant findings from studies presented at the 5th Advances in Circulating Tumour Cells (ACTC) conference. The research utilizing ANGLE's Parsortix system identified novel circulating tumor cell (CTC) biomarkers in ovarian and lung cancer, indicating potential for personalized treatment. A Phase II trial showed that gene analysis of CTCs could predict patient responses, with 85% survival for responders at 120 days. Additional studies highlighted the presence of p53 protein in small cell lung cancer and identified crucial markers for non-small cell lung cancer prognosis.
ANGLE plc has announced that a study from the Health Research Institute of Santiago demonstrates the effectiveness of the Parsortix system in assessing PD-L1 status in circulating tumor cells (CTCs) for non-small cell lung cancer (NSCLC) patients. This liquid biopsy method, which is safer than traditional tissue biopsies, offers a promising approach to monitor treatment responses. ANGLE is further developing a PD-L1 assay for use in cancer drug trials and aims to collaborate with leading cancer centers for validation. The study highlights the need for improved patient selection due to low response rates to current therapies.